CA3147704A1 - Method and use of pnpp-19 for preventing and treating eye diseases - Google Patents
Method and use of pnpp-19 for preventing and treating eye diseases Download PDFInfo
- Publication number
- CA3147704A1 CA3147704A1 CA3147704A CA3147704A CA3147704A1 CA 3147704 A1 CA3147704 A1 CA 3147704A1 CA 3147704 A CA3147704 A CA 3147704A CA 3147704 A CA3147704 A CA 3147704A CA 3147704 A1 CA3147704 A1 CA 3147704A1
- Authority
- CA
- Canada
- Prior art keywords
- pnpp
- eye
- glaucoma
- peptide
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895252P | 2019-09-03 | 2019-09-03 | |
| US62/895,252 | 2019-09-03 | ||
| US17/008,794 | 2020-09-01 | ||
| US17/008,794 US20210060125A1 (en) | 2019-09-03 | 2020-09-01 | METHOD AND USE OF PnPP-19 FOR PREVENTING AND TREATING EYE DISEASES |
| PCT/BR2020/050349 WO2021042193A1 (en) | 2019-09-03 | 2020-09-01 | Method and use of pnpp-19 for preventing and treating eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3147704A1 true CA3147704A1 (en) | 2021-03-11 |
Family
ID=74682721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3147704A Pending CA3147704A1 (en) | 2019-09-03 | 2020-09-01 | Method and use of pnpp-19 for preventing and treating eye diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210060125A1 (https=) |
| EP (1) | EP4025234A4 (https=) |
| JP (1) | JP2022547231A (https=) |
| KR (1) | KR20220084011A (https=) |
| CN (1) | CN114302734A (https=) |
| BR (1) | BR112022003759A2 (https=) |
| CA (1) | CA3147704A1 (https=) |
| WO (1) | WO2021042193A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024168415A1 (en) * | 2023-02-17 | 2024-08-22 | Biozeus Biopharmaceutical S.A. | Topical peptide formulation for the treatment of sexual dysfunction |
| WO2025133214A1 (en) | 2023-12-21 | 2025-06-26 | Novaliq Gmbh | Ophthalmic polypeptide compositions for the treatment of posterior eye disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005097137A (ja) * | 2003-09-22 | 2005-04-14 | Tokyoto Igaku Kenkyu Kiko | 糖尿病性網膜症の予防又は治療剤 |
| JP2011219412A (ja) * | 2010-04-09 | 2011-11-04 | Saisentan Igaku Kenkyusho:Kk | 緑内障の視野改善治療薬 |
| US8759298B2 (en) * | 2010-05-03 | 2014-06-24 | Scott & White Healthcare | Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration |
| MX362058B (es) * | 2012-08-20 | 2019-01-07 | Univ Federal De Minas Gerais Ufmg | Péptido pntx(19) sintético, composición farmacéutica y uso. |
| GB201401453D0 (en) * | 2014-01-28 | 2014-03-12 | Univ Birmingham | Transmucosal and transepithelial drug delivery system |
| BR102014010268B1 (pt) * | 2014-04-29 | 2021-12-28 | Universidade Federal De Minas Gerais - Ufmg | Uso do peptídeo sintético pntx-19 para tratamento de dor |
| WO2017068388A2 (pt) * | 2015-09-18 | 2017-04-27 | Universidade Federal De Minas Gerais - Ufmg | Uso do peptideo sintetico pntx-19 para tratamento de dor |
-
2020
- 2020-09-01 CA CA3147704A patent/CA3147704A1/en active Pending
- 2020-09-01 WO PCT/BR2020/050349 patent/WO2021042193A1/en not_active Ceased
- 2020-09-01 CN CN202080061721.7A patent/CN114302734A/zh active Pending
- 2020-09-01 US US17/008,794 patent/US20210060125A1/en not_active Abandoned
- 2020-09-01 BR BR112022003759A patent/BR112022003759A2/pt unknown
- 2020-09-01 KR KR1020227006863A patent/KR20220084011A/ko not_active Abandoned
- 2020-09-01 EP EP20860001.5A patent/EP4025234A4/en not_active Withdrawn
- 2020-09-01 JP JP2022539453A patent/JP2022547231A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022003759A2 (pt) | 2022-05-31 |
| JP2022547231A (ja) | 2022-11-10 |
| US20210060125A1 (en) | 2021-03-04 |
| CN114302734A (zh) | 2022-04-08 |
| EP4025234A1 (en) | 2022-07-13 |
| WO2021042193A1 (en) | 2021-03-11 |
| KR20220084011A (ko) | 2022-06-21 |
| EP4025234A4 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11464825B2 (en) | Adiponectin peptidomimetics for treating ocular disorders | |
| US20180296630A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| US20230348534A1 (en) | Sap and peptidomimetics for treatment of eye disease | |
| KR101906494B1 (ko) | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 | |
| US20210060125A1 (en) | METHOD AND USE OF PnPP-19 FOR PREVENTING AND TREATING EYE DISEASES | |
| US20240065999A1 (en) | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | |
| HK40027227A (en) | Adiponectin peptidomimetics for treating ocular disorders | |
| JP2020535117A (ja) | 眼疾患を治療するためのアディポネクチンペプチド模倣薬 | |
| HK1246178B (en) | Adiponectin peptidomimetics for treating ocular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240816 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240828 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240828 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241115 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |